212 related articles for article (PubMed ID: 23033003)
1. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.
Som A; Tu SM; Liu J; Wang X; Qiao W; Logothetis C; Corn PG
Br J Cancer; 2012 Oct; 107(9):1547-53. PubMed ID: 23033003
[TBL] [Abstract][Full Text] [Related]
2. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
Rajpar S; Massard C; Laplanche A; Tournay E; Gross-Goupil M; Loriot Y; Di Palma M; Bossi A; Escudier B; Chauchereau A; Fizazi K
Ann Oncol; 2010 Sep; 21(9):1864-1869. PubMed ID: 20181574
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
[TBL] [Abstract][Full Text] [Related]
4. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
[TBL] [Abstract][Full Text] [Related]
5. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
6. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
[TBL] [Abstract][Full Text] [Related]
7. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.
Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F; Smith MR
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3361-7. PubMed ID: 16740758
[TBL] [Abstract][Full Text] [Related]
8. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.
Izumi K; Mizokami A; Itai S; Shima T; Shigehara K; Miwa S; Maeda Y; Konaka H; Koh E; Namiki M
BJU Int; 2012 Feb; 109(3):394-400. PubMed ID: 21599822
[TBL] [Abstract][Full Text] [Related]
9. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.
Metwalli AR; Rosner IL; Cullen J; Chen Y; Brand T; Brassell SA; Lesperance J; Porter C; Sterbis J; McLeod DG
Urol Oncol; 2014 Aug; 32(6):761-8. PubMed ID: 24929891
[TBL] [Abstract][Full Text] [Related]
10. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
Sonpavde G; Pond GR; Berry WR; de Wit R; Armstrong AJ; Eisenberger MA; Tannock IF
Urol Oncol; 2012 Sep; 30(5):607-13. PubMed ID: 20888271
[TBL] [Abstract][Full Text] [Related]
11. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Lorente JA; Valenzuela H; Morote J; Gelabert A
Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
Antonarakis ES; Heath EI; Posadas EM; Yu EY; Harrison MR; Bruce JY; Cho SY; Wilding GE; Fetterly GJ; Hangauer DG; Kwan MF; Dyster LM; Carducci MA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):883-92. PubMed ID: 23314737
[TBL] [Abstract][Full Text] [Related]
13. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.
Saad F; Eastham JA; Smith MR
Urol Oncol; 2012; 30(4):369-78. PubMed ID: 21163673
[TBL] [Abstract][Full Text] [Related]
14. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
[TBL] [Abstract][Full Text] [Related]
15. The value of tumor markers in men with metastatic prostate cancer undergoing [
Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
[TBL] [Abstract][Full Text] [Related]
16. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
Smith MR; Kabbinavar F; Saad F; Hussain A; Gittelman MC; Bilhartz DL; Wynne C; Murray R; Zinner NR; Schulman C; Linnartz R; Zheng M; Goessl C; Hei YJ; Small EJ; Cook R; Higano CS
J Clin Oncol; 2005 May; 23(13):2918-25. PubMed ID: 15860850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]